These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 10716495)

  • 1. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
    Carr A; Miller J; Eisman JA; Cooper DA
    AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents.
    Chapplain JM; Beillot J; Begue JM; Souala F; Bouvier C; Arvieux C; Tattevin P; Dupont M; Chapon F; Duvauferrier R; Hespel JP; Rochcongar P; Michelet C
    J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1477-88. PubMed ID: 15602126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
    Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
    HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
    Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper DA;
    AIDS; 2001 Sep; 15(14):1811-22. PubMed ID: 11579243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
    Haubrich RH; Riddler SA; DiRienzo AG; Komarow L; Powderly WG; Klingman K; Garren KW; Butcher DL; Rooney JF; Haas DW; Mellors JW; Havlir DV;
    AIDS; 2009 Jun; 23(9):1109-18. PubMed ID: 19417580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
    Dieterich DT
    AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
    Carr A; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA
    Lancet; 1999 Jun; 353(9170):2093-9. PubMed ID: 10382692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient.
    Bleeker-Rovers CP; Kadir SW; van Leusen R; Richter C
    Neth J Med; 2000 Nov; 57(5):190-3. PubMed ID: 11063865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
    Lonergan JT; Barber RE; Mathews WC
    AIDS; 2003 Nov; 17(17):2495-9. PubMed ID: 14600521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
    Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
    Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
    Mallal SA; John M; Moore CB; James IR; McKinnon EJ
    AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
    AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
    Saint-Marc T; Partisani M; Poizot-Martin I; Rouviere O; Bruno F; Avellaneda R; Lang JM; Gastaut JA; Touraine JL
    AIDS; 2000 Jan; 14(1):37-49. PubMed ID: 10714566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.